Technical Analysis for OPTN - OptiNose, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
7.04 | 0.14% | 0.01 |
OPTN closed up 0.14 percent on Tuesday, January 15, 2019, on approximately normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical OPTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 15 | 20 DMA Support | Bullish | 0.00% |
| Jan 15 | Hammer Candlestick | Bullish | 0.00% |
| Jan 15 | Doji - Bullish? | Reversal | 0.00% |
| Jan 14 | 180 Bearish Setup | Bearish Swing Setup | 0.14% |
| Jan 14 | Wide Bands | Range Expansion | 0.14% |
| Jan 11 | 20 DMA Support | Bullish | -3.03% |
| Jan 11 | Wide Bands | Range Expansion | -3.03% |
| Jan 10 | Wide Bands | Range Expansion | -0.85% |
| Jan 9 | Wide Bands | Range Expansion | -7.00% |
| Jan 8 | 1,2,3 Retracement Bearish | Bearish Swing Setup | -1.95% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-26
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more OPTN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 30.0 |
| 52 Week Low | 5.66 |
| Average Volume | 268,843 |
| 200-Day Moving Average | 16.5341 |
| 50-Day Moving Average | 8.3514 |
| 20-Day Moving Average | 6.841 |
| 10-Day Moving Average | 7.13 |
| Average True Range | 0.6749 |
| ADX | 29.52 |
| +DI | 15.5975 |
| -DI | 22.3522 |
| Chandelier Exit (Long, 3 ATRs ) | 6.425299999999999 |
| Chandelier Exit (Short, 3 ATRs ) | 7.6847 |
| Upper Bollinger Band | 7.8066 |
| Lower Bollinger Band | 5.8754 |
| Percent B (%b) | 0.6 |
| BandWidth | 28.229791 |
| MACD Line | -0.2762 |
| MACD Signal Line | -0.426 |
| MACD Histogram | 0.1498 |
| Fundamentals | Value |
|---|---|
| Market Cap | 265.84 Million |
| Num Shares | 37.8 Million |
| EPS | -19.61 |
| Price-to-Earnings (P/E) Ratio | -0.36 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.94 | ||||
| Resistance 3 (R3) | 7.87 | 7.49 | 7.79 | ||
| Resistance 2 (R2) | 7.49 | 7.26 | 7.53 | 7.74 | |
| Resistance 1 (R1) | 7.27 | 7.12 | 7.34 | 7.34 | 7.69 |
| Pivot Point | 6.89 | 6.89 | 6.93 | 6.93 | 6.89 |
| Support 1 (S1) | 6.67 | 6.66 | 6.74 | 6.74 | 6.39 |
| Support 2 (S2) | 6.29 | 6.52 | 6.33 | 6.34 | |
| Support 3 (S3) | 6.07 | 6.29 | 6.29 | ||
| Support 4 (S4) | 6.14 |
